Drug Approval | June 17, 2024
USFDA approves next-gen TKI Augtyro for treatment of solid tumors
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors